Nilay Akagun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nilay Akagun has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ugur Emrah Altiparmak
Acıbadem Ankara Hospital, Clinic of Ophthalmology, Ankara, Türkiye
6 shared publications Pa Ozer
Department of Ophthalmology, Faculty of Medicine, Ufuk University, Ankara, Turkey
1 shared publicationS Gazyagci
Department of Ophthalmology, Private Veni Vidi Eye Health Center, Ankara, Turkey
1 shared publicationUgur Emrah Altiparmak
Department of Clinical Ophthalmology, Acibadem Hospital, Ankara, Turkey
1 shared publication
Latest Publications
- Open Access
Real-World Effectiveness of CARE-Based Spectacle Lenses for Myopia Control in a Turkish Pediatric Cohort
Childhood myopia progression remains a major global public health concern, and spectacle lenses designed to induce peripheral myopic defocus have emerged as a non-pharmacological strategy for myopia control; however, real-world evidence from European populations remains limited. This retrospective observational study evaluated the 12-month real-world effectiveness of cylindrical annular refractive element spectacle lenses in a Turkish pediatric cohort. Children aged 5–15 years who wore myopia-control spectacle lenses from the CARE platform or single-vision lenses were included. Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline and at 12 months. The primary outcomes were 12-month changes in SER and AL. Multivariable generalized estimation equations were applied to account for inter-eye correlation and to adjust for age and gender. A total of 168 eyes were analyzed (85 with single-vision lenses; 83 with myopia-control lenses). After 12 months, the myopia-control group demonstrated significantly slower progression than the single-vision group, with mean SER changes of −0.40 ± 0.92 D versus −0.77 ± 0.74 D and axial elongation of 0.17 ± 0.25 mm versus 0.31 ± 0.30 mm, respectively. Treatment group remained a significant predictor of both refractive progression (p = 0.008) and axial elongation (p = 0.003). Age was independently associated with axial length change (p < 0.001), whereas gender was not. These findings provide real-world European evidence supporting the role of defocus-modulating spectacle lenses in pediatric myopia management.
Open AccessReal-World Effectiveness of CARE-Based Spectacle Lenses for Myopia Control in a Turkish Pediatric Cohort
Childhood myopia progression remains a major global public health concern, and spectacle lenses designed to induce peripheral myopic defocus have emerged as a non-pharmacological strategy for myopia control; however, real-world evidence from European populations remains limited. This retrospective observational study evaluated the 12-month real-world effectiveness of cylindrical annular refractive element spectacle lenses in a Turkish pediatric cohort. Children aged 5–15 years who wore myopia-control spectacle lenses from the CARE platform or single-vision lenses were included. Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline and at 12 months. The primary outcomes were 12-month changes in SER and AL. Multivariable generalized estimation equations were applied to account for inter-eye correlation and to adjust for age and gender. A total of 168 eyes were analyzed (85 with single-vision lenses; 83 with myopia-control lenses). After 12 months, the myopia-control group demonstrated significantly slower progression than the single-vision group, with mean SER changes of −0.40 ± 0.92 D versus −0.77 ± 0.74 D and axial elongation of 0.17 ± 0.25 mm versus 0.31 ± 0.30 mm, respectively. Treatment group remained a significant predictor of both refractive progression (p = 0.008) and axial elongation (p = 0.003). Age was independently associated with axial length change (p < 0.001), whereas gender was not. These findings provide real-world European evidence supporting the role of defocus-modulating spectacle lenses in pediatric myopia management.
- Open Access
- 18 February 2026
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 56 (1) , 8-15
Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study
Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study - Turkish Journal of Ophthalmology
- 18 February 2026
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 56 (1) , 8-15
Open AccessReal-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study
Real-World Comparison of the Effectiveness of Defocus Incorporated Multiple Segments and Myopi-X Spectacle Lenses for Myopia Control in Turkish Children: A Retrospective Study - Turkish Journal of Ophthalmology
- Open Access
Real-World Effectiveness of DIMS Spectacle Lenses for Myopia Control in a Turkish Pediatric Population: A Retrospective Study Using Age-Specific Physiological Growth Curves
Background/Objectives: This study aimed to evaluate the one-year real-world effectiveness of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in controlling myopia progression in a Turkish pediatric cohort and to identify predictors of treatment response using age-specific physiological growth curves. Methods: This retrospective single-center study included 54 patients (108 eyes) aged 6–16 years with myopia who wore DIMS spectacle lenses full time for 12 months. The primary outcomes were spherical equivalent refraction (SER) success and axial length (AL)-based treatment response. Treatment success was defined as an SER progression of ≤0.50 dioptres per year and AL elongation within age-specific physiological limits. Subgroup analyses were performed according to age, gender, and the baseline AL group. Results: After 12 months, the mean AL elongation was 0.14 ± 0.31 mm, and the mean SER change was −0.28 ± 0.42 D. SER-based success was achieved in 85.2% of eyes. For AL-based response, 61.1% of eyes showed a good response, 16.7% showed a low–moderate response, and 22.2% had no response. Eyes with moderate baseline AL exhibited significantly less axial elongation than those with high baseline AL (p = 0.001). Children aged ≥ 10 years demonstrated better AL-based responses (p = 0.016). The baseline AL group significantly predicted the AL treatment response, while both the baseline AL group and gender predicted SER success. Gender was associated with SER outcomes but not with AL-based response. Conclusions: DIMS spectacle lenses effectively reduced myopia progression and axial elongation in this real-world Turkish pediatric cohort. Baseline AL and gender were significant predictors of treatment outcomes. Incorporating age-specific physiological growth curves provided an individualized framework for interpreting treatment success. Further prospective studies with larger samples and longer follow-up are warranted to confirm these findings.
Open AccessReal-World Effectiveness of DIMS Spectacle Lenses for Myopia Control in a Turkish Pediatric Population: A Retrospective Study Using Age-Specific Physiological Growth Curves
Background/Objectives: This study aimed to evaluate the one-year real-world effectiveness of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in controlling myopia progression in a Turkish pediatric cohort and to identify predictors of treatment response using age-specific physiological growth curves. Methods: This retrospective single-center study included 54 patients (108 eyes) aged 6–16 years with myopia who wore DIMS spectacle lenses full time for 12 months. The primary outcomes were spherical equivalent refraction (SER) success and axial length (AL)-based treatment response. Treatment success was defined as an SER progression of ≤0.50 dioptres per year and AL elongation within age-specific physiological limits. Subgroup analyses were performed according to age, gender, and the baseline AL group. Results: After 12 months, the mean AL elongation was 0.14 ± 0.31 mm, and the mean SER change was −0.28 ± 0.42 D. SER-based success was achieved in 85.2% of eyes. For AL-based response, 61.1% of eyes showed a good response, 16.7% showed a low–moderate response, and 22.2% had no response. Eyes with moderate baseline AL exhibited significantly less axial elongation than those with high baseline AL (p = 0.001). Children aged ≥ 10 years demonstrated better AL-based responses (p = 0.016). The baseline AL group significantly predicted the AL treatment response, while both the baseline AL group and gender predicted SER success. Gender was associated with SER outcomes but not with AL-based response. Conclusions: DIMS spectacle lenses effectively reduced myopia progression and axial elongation in this real-world Turkish pediatric cohort. Baseline AL and gender were significant predictors of treatment outcomes. Incorporating age-specific physiological growth curves provided an individualized framework for interpreting treatment success. Further prospective studies with larger samples and longer follow-up are warranted to confirm these findings.
- 20 May 2025
- Published by Springer Nature in Ophthalmic and Physiological Optics
- Vol. 45 (5) , 1090-1097
Defocus incorporated multiple segments spectacle lenses for myopia control: A retrospective study in a Turkish cohort
Purpose: This study evaluated the effectiveness of defocus incorporated multiple segments (DIMS) spectacle lenses in controlling myopia progression and axial elongation in a Turkish paediatric population over a 12‐month period. Methods: This retrospective observational study included 97 children (194 eyes), aged 6–16 years, who were prescribed either DIMS lenses ( n = 54) or single vision spectacle lenses (SVSLs, n = 43). Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline and after 12 months. Treatment effectiveness was assessed using generalised estimating equations (GEE) and subgroup analyses were conducted based on age group, gender and baseline AL. Results: After 12 months, the DIMS group exhibited significantly less myopia progression (−0.28 D [0.42]) compared with the SVSL group (−0.74 D [0.75]), indicating a 62% reduction in SER progression ( p < 0.001). Axial elongation was also significantly lower in the DIMS group (0.14 mm [0.31]) than in the SVSL group (0.29 mm [0.31]), corresponding to a 52% reduction ( p < 0.001). Subgroup analyses revealed that younger age and high baseline AL were consistently associated with greater SER progression and AL elongation across both groups. In the DIMS group, high baseline AL predicted poorer outcomes, but age and gender were not significant predictors. Conclusions: DIMS spectacle lenses effectively reduced myopia progression and axial elongation in children compared with SVSLs. These lenses offer a safe and non‐invasive method for myopia control, being especially beneficial for younger patients or those with higher baseline axial length.
- 20 May 2025
- Published by Springer Nature in Ophthalmic and Physiological Optics
- Vol. 45 (5) , 1090-1097
Defocus incorporated multiple segments spectacle lenses for myopia control: A retrospective study in a Turkish cohort
Purpose: This study evaluated the effectiveness of defocus incorporated multiple segments (DIMS) spectacle lenses in controlling myopia progression and axial elongation in a Turkish paediatric population over a 12‐month period. Methods: This retrospective observational study included 97 children (194 eyes), aged 6–16 years, who were prescribed either DIMS lenses ( n = 54) or single vision spectacle lenses (SVSLs, n = 43). Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline and after 12 months. Treatment effectiveness was assessed using generalised estimating equations (GEE) and subgroup analyses were conducted based on age group, gender and baseline AL. Results: After 12 months, the DIMS group exhibited significantly less myopia progression (−0.28 D [0.42]) compared with the SVSL group (−0.74 D [0.75]), indicating a 62% reduction in SER progression ( p < 0.001). Axial elongation was also significantly lower in the DIMS group (0.14 mm [0.31]) than in the SVSL group (0.29 mm [0.31]), corresponding to a 52% reduction ( p < 0.001). Subgroup analyses revealed that younger age and high baseline AL were consistently associated with greater SER progression and AL elongation across both groups. In the DIMS group, high baseline AL predicted poorer outcomes, but age and gender were not significant predictors. Conclusions: DIMS spectacle lenses effectively reduced myopia progression and axial elongation in children compared with SVSLs. These lenses offer a safe and non‐invasive method for myopia control, being especially beneficial for younger patients or those with higher baseline axial length.
- Open Access
- 25 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 55 (2) , 61-66
Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye
Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye - Turkish Journal of Ophthalmology
- 25 April 2025
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 55 (2) , 61-66
Open AccessEvaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye
Evaluation of Reasons for Discontinuation of Atropine 0.01% in Myopia Management: A Single-Center Retrospective Study from Türkiye - Turkish Journal of Ophthalmology
- Open Access
- 17 April 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-9
Myopi-X lenses vs. low-dose atropine in myopia control: a Turkish retrospective study
The global prevalence of myopia is rising rapidly, with projections indicating that by 2050, half of the world’s population will be affected. High myopia is associated with an increased risk of sight-threatening complications, contributing to a substantial public health burden. Atropine 0.01% has been widely used for myopia control in non-Asian populations, supported by evidence demonstrating its efficacy. Myopi-X® lenses, designed to induce myopic defocus, represent an optical alternative to pharmacological intervention. Given that atropine requires monthly preparation, long-term adherence, and may cause mild side effects, (Myopi-X® Novax®) lenses offer a non-pharmacological option that may be preferable for some patients. This study compares the effectiveness of these two treatment strategies in comparison with single vision lenses to provide further insights into their role in myopia management. This retrospective observational study was conducted at Acıbadem Hospital, Ankara, between September 2022 and September 2023. A total of 128 patients aged 5 to 16 years with myopia were included and divided into three groups: peripheral progressive addition lenses (Myopi-X® Novax®), atropine 0.01%, and single vision lenses. Baseline characteristics, including age, gender, and axial length, were recorded. Cycloplegic autorefraction and axial length measurements were performed, and statistical analyses were conducted to assess changes in spherical equivalent refraction and axial length over 12 months. Additionally, the potential effects of baseline axial length, gender, and age group on spherical equivalent progression and axial length elongation were evaluated. Significant differences were observed among the treatment groups in changes in spherical equivalent refraction and axial length (p < 0.001). Both the Myopi-X® lenses and atropine 0.01% groups exhibited significantly less myopia progression compared to the single vision lenses group (p < 0.001 for both). However, no significant difference was observed between the Myopi-X® lenses and atropine 0.01% groups at 12 months (p = 0.79), and axial length changes remained comparable between these two groups (p = 0.76). Regarding potential confounding factors, age had a significant effect on spherical equivalent refraction progression, with older children experiencing less myopic progression (p = 0.02), whereas no significant effect was observed on axial length change (p = 0.11). Gender was not significantly associated with changes in spherical equivalent (p = 0.21) or axial length (p = 0.32). Similarly, baseline axial length showed no significant association with changes in spherical equivalent (p = 0.17) or axial length (p = 0.36). Both Myopi-X® lenses and atropine 0.01% effectively slowed myopia progression over 12 months compared to single vision lenses. Spherical equivalent progression and axial length elongation were comparable between these two treatment groups. Gender and baseline axial length did not significantly affect the outcomes, whereas older children exhibited less myopic progression in terms of spherical equivalent change. This study aimed to compare the clinical effectiveness of these two treatment strategies. Further studies with longer follow-up periods are required to evaluate the long-term sustainability of these effects.
- 17 April 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-9
Open AccessMyopi-X lenses vs. low-dose atropine in myopia control: a Turkish retrospective study
The global prevalence of myopia is rising rapidly, with projections indicating that by 2050, half of the world’s population will be affected. High myopia is associated with an increased risk of sight-threatening complications, contributing to a substantial public health burden. Atropine 0.01% has been widely used for myopia control in non-Asian populations, supported by evidence demonstrating its efficacy. Myopi-X® lenses, designed to induce myopic defocus, represent an optical alternative to pharmacological intervention. Given that atropine requires monthly preparation, long-term adherence, and may cause mild side effects, (Myopi-X® Novax®) lenses offer a non-pharmacological option that may be preferable for some patients. This study compares the effectiveness of these two treatment strategies in comparison with single vision lenses to provide further insights into their role in myopia management. This retrospective observational study was conducted at Acıbadem Hospital, Ankara, between September 2022 and September 2023. A total of 128 patients aged 5 to 16 years with myopia were included and divided into three groups: peripheral progressive addition lenses (Myopi-X® Novax®), atropine 0.01%, and single vision lenses. Baseline characteristics, including age, gender, and axial length, were recorded. Cycloplegic autorefraction and axial length measurements were performed, and statistical analyses were conducted to assess changes in spherical equivalent refraction and axial length over 12 months. Additionally, the potential effects of baseline axial length, gender, and age group on spherical equivalent progression and axial length elongation were evaluated. Significant differences were observed among the treatment groups in changes in spherical equivalent refraction and axial length (p < 0.001). Both the Myopi-X® lenses and atropine 0.01% groups exhibited significantly less myopia progression compared to the single vision lenses group (p < 0.001 for both). However, no significant difference was observed between the Myopi-X® lenses and atropine 0.01% groups at 12 months (p = 0.79), and axial length changes remained comparable between these two groups (p = 0.76). Regarding potential confounding factors, age had a significant effect on spherical equivalent refraction progression, with older children experiencing less myopic progression (p = 0.02), whereas no significant effect was observed on axial length change (p = 0.11). Gender was not significantly associated with changes in spherical equivalent (p = 0.21) or axial length (p = 0.32). Similarly, baseline axial length showed no significant association with changes in spherical equivalent (p = 0.17) or axial length (p = 0.36). Both Myopi-X® lenses and atropine 0.01% effectively slowed myopia progression over 12 months compared to single vision lenses. Spherical equivalent progression and axial length elongation were comparable between these two treatment groups. Gender and baseline axial length did not significantly affect the outcomes, whereas older children exhibited less myopic progression in terms of spherical equivalent change. This study aimed to compare the clinical effectiveness of these two treatment strategies. Further studies with longer follow-up periods are required to evaluate the long-term sustainability of these effects.
- Open Access
- 5 February 2025
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 55 (1) , 1-5
Combination Therapy with Atropine 0.05% and Myopi-X® Glasses: Is it Effective in Myopia Control?
To investigate whether the combination therapy of Myopi-X® peripheral progressive addition lenses (PAL; Novax®) and atropine 0.05% provides an additive effect compared to monotherapies with either Myopi-X® PAL or atropine 0.05%. This retrospective cross-sectional study reviewed the clinical records of 51 patients, categorized into three groups: 27 in the Myopi-X group, 13 in the atropine 0.05% group, and 11 in the combination therapy group using Myopi-X peripheral PAL with atropine 0.05%. Baseline characteristics, including age, cycloplegic spherical equivalent (SE), and axial length (AL), were compared between the groups. Twelve months after treatment initiation, changes in SE and AL were assessed and compared between the groups. Among the 51 patients analyzed, the baseline characteristics differed significantly between the groups, with the atropine 0.05% group showing a higher average age, longer AL, and lower SE compared to the other groups. After 12 months, no significant differences were found in SE changes between the treatment groups (p=0.35). Similarly, changes in AL did not significantly differ between the groups (p=0.10), although age had a significant impact on AL change (p=0.01). No significant differences were observed in pairwise comparisons of SE or AL changes between the groups. In this study, combining atropine 0.05% with Myopi-X PALs did not provide an additive benefit. The literature suggests that both treatments are effective in slowing myopia progression individually; however, in our study, their combination did not significantly improve SE progression or axial elongation compared to monotherapies. Further randomized studies with larger patient groups are needed to confirm these findings and assess long-term effects.
- 5 February 2025
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 55 (1) , 1-5
Open AccessCombination Therapy with Atropine 0.05% and Myopi-X® Glasses: Is it Effective in Myopia Control?
To investigate whether the combination therapy of Myopi-X® peripheral progressive addition lenses (PAL; Novax®) and atropine 0.05% provides an additive effect compared to monotherapies with either Myopi-X® PAL or atropine 0.05%. This retrospective cross-sectional study reviewed the clinical records of 51 patients, categorized into three groups: 27 in the Myopi-X group, 13 in the atropine 0.05% group, and 11 in the combination therapy group using Myopi-X peripheral PAL with atropine 0.05%. Baseline characteristics, including age, cycloplegic spherical equivalent (SE), and axial length (AL), were compared between the groups. Twelve months after treatment initiation, changes in SE and AL were assessed and compared between the groups. Among the 51 patients analyzed, the baseline characteristics differed significantly between the groups, with the atropine 0.05% group showing a higher average age, longer AL, and lower SE compared to the other groups. After 12 months, no significant differences were found in SE changes between the treatment groups (p=0.35). Similarly, changes in AL did not significantly differ between the groups (p=0.10), although age had a significant impact on AL change (p=0.01). No significant differences were observed in pairwise comparisons of SE or AL changes between the groups. In this study, combining atropine 0.05% with Myopi-X PALs did not provide an additive benefit. The literature suggests that both treatments are effective in slowing myopia progression individually; however, in our study, their combination did not significantly improve SE progression or axial elongation compared to monotherapies. Further randomized studies with larger patient groups are needed to confirm these findings and assess long-term effects.
- Open Access
- 1 January 2020
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 23 (1) , 123-124
Rapid healing of a persistent corneal epithelial defect (PCED) with autologous serum treatment
Best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/200 in the left eye. Slit lamp examination revealed a central corneal epithelial defect on the left eye and the right eye was normal. Corneal epithelial defect appeared after left upper eyelid chalazion surgery and persisted for 2 months without any response to treatment with eye patching, bandage contact lenses, and artificial eyedrops. We started the treatment with ASD six times daily and preservative-free netilmicin eyedrops four times daily to prevent infection. The drops were used simultaneously with eyepatching for the first two days. The eye was left unpatched after the second day. The corneal epithelial defect resolved after 48 hours. We did not detect a new epithelial defect in the follow up visits. ASD is a quick, safe, and effective treatment option in persistent epithelial defect cases....
- 1 January 2020
- Published by Medknow in Nigerian Journal of Clinical Practice
- Vol. 23 (1) , 123-124
Open AccessRapid healing of a persistent corneal epithelial defect (PCED) with autologous serum treatment
Best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/200 in the left eye. Slit lamp examination revealed a central corneal epithelial defect on the left eye and the right eye was normal. Corneal epithelial defect appeared after left upper eyelid chalazion surgery and persisted for 2 months without any response to treatment with eye patching, bandage contact lenses, and artificial eyedrops. We started the treatment with ASD six times daily and preservative-free netilmicin eyedrops four times daily to prevent infection. The drops were used simultaneously with eyepatching for the first two days. The eye was left unpatched after the second day. The corneal epithelial defect resolved after 48 hours. We did not detect a new epithelial defect in the follow up visits. ASD is a quick, safe, and effective treatment option in persistent epithelial defect cases....